Gold bars to be exempt from tariffs, White House clarifies
Investing.com -- Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company’s fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key product Elocta fell short, missing estimates by 13%. The shortfall was attributed to an order phasing headwind in Q4 in International markets.
However, the company’s Haemophilia royalty from Sanofi (NASDAQ:SNY) outperformed, coming in 8% higher than anticipated, a reflection of Sanofi’s robust portfolio performance.
Specialty care sales also exceeded expectations, beating consensus by over 30%, showcasing the company’s strength in this area. Despite these highlights, the stock’s decline indicates investor concern over the mixed results, particularly the underperformance of Elocta.
RBC analysts commented on the company’s future prospects, stating, "Overall, the 2024 performance is aligned with our mid term positive thesis, with a range of growth drivers (Altuvoct, Doptelet, Aspaveli, Beyfortus and Gamifant) underpinning robust (18%) top line growth.
This drove margin improvement in 2024 and should continue to do so in the medium term, albeit with a pause for reinvestment this year. While the guidance may see consensus earnings fall for 2025, the outlook is closely aligned with our forecasts."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.